Document is current

Article History

Received: 14 June 2024

Accepted: 4 December 2024

First Online: 29 January 2025

Competing interests

: DN, KCC, IDD, JBJ, JJ, YL, RKTH, AKB, MPD, JMF, CLL, SRM, MNM, RFP, SNR, and AR have no conflicting interests. BDG reports fees unrelated to this work from Sure Med Compliance and Elly Health. MMM reports research funding from Varian, a licensing agreement with Fuse Oncology, and serves in the AAPM Board of Directors and is the Co-Director of MROQC, funded by BCBSM. TJD is a member of the National Comprehensive Cancer Network (NCCN) NSCLC panel. JFTR reports stock ownership and leadership in Cvergenx, Inc. He reports IP and royalty rights in RSI, GARD, RxRSI. HHMY reports funding or fees unrelated to this work from the National Institute of Health, UpToDate, Novocure and Bristol-Myers Squib. IEN is on the scientific advisory of Endectra, LLC., co-founder of iRAI LLC, deputy editor for the journal of Medical Physics, co-chief editor of British Journal of Radiology (BJR)-AI and receives funding from the National Institute of Health (NIH), foundations, and Department of Defense (DoD). A PCT patent application for ARCliDS has been filed. Patent Title: Adaptive radiotherapy clinical decision support tool and related methods, Patent Applicant: H Lee Moffitt Cancer Center IP office in conjunction with University of Michigan IP office. Inventors: DN, IEN, RKTH, Wenbo Sun, JJ, IDD, KCC, MMM, and JBJ. Application Number: US2023/075004. Status of Application: Pending. Specific aspect of manuscript covered in patent application: The patent covers the underlying model-based decision-making framework of ARCliDS.